Biotech firm VeroScience obtained FDA approval for its Type 2 diabetes medicine Cycloset. The drug, which targets the body's dopamine activity, is the first product to receive clearance under guidelines that require drugmakers to prove their diabetes treatments do not raise the risk of cardiovascular disease.

Full Story:

Related Summaries